MDGL News and Press, Madrigal Pharmaceuticals Inc. From 06/11/24

2024-06-11 13:49:24 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Seeking Alpha’s Quant Rating on Akero Therapeutics Historical earnings data for Akero Therapeutics Financial information for Akero Therapeutics Re...

2024-06-11 13:28:02 ET More on Madrigal Pharmaceuticals Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madriga...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is one of today's top gainers. The company's shares have moved 10.99% on the day to $282.88. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for ...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-10 21:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for MDGL on June 10, 2024 07:10PM ET. MDGL was trading at $254.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 8 - Buy, 1 ...

2024-06-10 09:45:00 ET Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite the...

2024-06-09 08:47:48 ET Summary Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis. GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market. Madrigal's financ...

2024-06-07 11:15:07 ET Summary Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has become more volatile due to competition from other ...

2024-06-07 07:21:34 ET Summary Galectin Therapeutics is focused on developing therapies that target galectin proteins related to conditions such as metabolic dysfunction-associated steatohepatitis, cirrhosis, and cancer. Its leading drug candidate, belapectin, is a galectin-3 inhi...

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% o...